Intestinal perforation following anlotinib treatment in a non-small cell lung cancer patient
10.3760/cma.j.cn114015-20250106-00011
- VernacularTitle:安罗替尼致非小细胞肺癌患者肠穿孔
- Author:
Chunyan WANG
1
;
Shoubo CAO
;
Bing WU
;
Rui HENG
;
Wei LING
;
Guixiang WENG
Author Information
1. 山东第二医科大学附属临沂市人民医院临床药理研究病房，临沂 276003
- Publication Type:Journal Article
- Keywords:
Intestinal perforation;
Carcinoma, non-small-cell lung;
Angiogenesis inhibitors;
Anlotinib
- From:
Adverse Drug Reactions Journal
2025;27(11):702-704
- CountryChina
- Language:Chinese
-
Abstract:
A 75-year-old male patient with non-small cell lung cancer in the lower lobe of the left lung underwent left lobectomy, followed by 4 cycles of adjuvant chemotherapy with paclitaxel and platinum, 4 cycles of chemotherapy with docetaxel and cisplatin, and immunotherapy with sintilimab, 13 cycles of immunotherapy with sintilimab monotherapy, and 5 cycles of endostatin and sintilimab, spanning a total of 5 years. Due to disease progression, he received the monotherapy with anlotinib, 42 days later, the patient developed intestinal perforation, and laparoscopic ileal perforation repair surgery was performed. During the operation, a perforation with a diameter of about 1 cm was observed in the ileum, indicating the outflow of digestive fluid and a large amount of purulent fluid accumulation in the pelvic cavity; no signs of gastrointestinal tumor metastasis were observed. After surgery, the patient developed abdominal infection and peritonitis, and was given symptomatic and supportive treatments such as anti-infection for 7 days. However, the patient developed severe complications such as lung infection, heart failure, sepsis, and respiratory failure, and died.
